| Metric | Value (₹ Cr) |
|---|---|
| Revenue | 716.38 |
| Total Income | 718.06 |
| Expenditure | 652.80 |
| PBT | 65.26 |
| Net Profit | 50.48 |
| OPM | 9.97% |
| NPM | 7.03% |
| EPS | 7.00 |
₹716 Crore Revenue Growth Masks Margin Deterioration Below Guidance
Record volume growth and revenue (+145% YoY) collapse into compressed profit growth (+47% YoY). The call reveals why: 2-2.5% of reported margins are unrealized inventory gains, and normalized performance sits below prior guidance.
₹50.5 Cr
+47% YoY · 7.05% margin
~2-2.5pp
From FIFO-to-WAC change
~₹36-38 Cr
~5% margin (incl. startup costs)
On paper, Shanti Gold's Q1 looks exceptional: ₹716.4 Cr revenue (the highest ever) and ₹50.5 Cr profit, both crushing prior year. But the divergence between revenue growth (+145%) and profit growth (+47%) tells a different story. Volume surged 61% YoY, validating the organized jewelry retail shift — yet profitability lagged. The call explains why, and the answer complicates the investment case.
Where the margin gap came from
Management discloses upfront: 2 to 2.5 percentage points of the reported 9.97% EBITDA margin are unrealized gains from an accounting change (FIFO to weighted-average cost method on gold inventory). Strip that out, and normalized EBITDA margin sits at 7.5–8%, well below the current reported 9.97%. The same inventory windfall flows to PAT — reported 7.05% margin includes roughly 2pp of non-recurring gain, meaning normalized PAT margin is closer to 5%, not 7%.
Roughly 2% to 2.5% was the inventory gain. Going forward, looking at the current demand and all, we should be in the range of 7.5% to 8% EBITDA.
This matters because it repositions the quarter: strong volume (+61% YoY) and revenue (+145% YoY) are real and validate the market tailwind from organized retail consolidation. But the profit conversion is deteriorating, not expanding. On a same-for-same margin basis (excluding inventory gains), Q1 PAT margin (~5%) is below the company's own prior guidance from the FY-2026 call (4% core PAT margin going forward). Management reiterated that 4% core target on this call — meaning normalized Q1 performance missed its own anchor.
Management's claims vs. what holds up
Strong volume expansion driving growth
61% volume YoY achieved; but FY27 volume guidance downgraded from 35–40% to 30–40%
Supported, but guidance cut
EBITDA margin sustainable at 10%
2–2.5pp of current 9.97% is unrealized inventory gain; normalized 7.5–8%
Overstated
PAT margins healthy at 7%
7.05% reported; 2pp from temporary inventory gains; core target 4%
Overstated
Marol facility provides growth enabler
Commenced June 2026, only 1 month in Q1; early-stage, better results promised ahead
Supported (early stage)
FY27 guidance of ₹3,500 Cr remains firm
Management 'sticking to' ₹3,500 Cr but hedged with caveats and possibility to revise if Q3 demand strong
Partial (caveat-heavy)
What changed on this call
Guidance was formally downgraded across the board, signaling management caution despite Q1's strong headline numbers:
Volume growth: 35–40% → 30–40% (floor cut 5pp, ceiling unchanged)
Value growth: 60–70% → 50–60% (both ends compressed by 10pp)
EBITDA margin: Restated at 7.5–8% core (below current 9.97% reported)
Capex: ₹47 Cr Jaipur facility (1,200 kg, 3 acres), ₹100 Cr rights issue required
Capital structure: Debt-to-equity rising to <1.0x from 0.50; working capital intensity acknowledged
The bull-bear ledger
61% volume growth in Q1 validates organized retail tailwind; structural demand durable
Studded jewellery mix (75% of revenue) and designer/Turkish categories driving ASP improvement
Marol facility + Jaipur capex (1,200 kg added) expand manufacturing flexibility; 75% current capacity utilization leaves room
Company still 0.00% market share in organized jewelry; multi-year runway for volume growth if macro holds
22-year manufacturing track record and customer relationship depth are credible execution moats
Reported profit (+47% YoY) and EBITDA margin (9.97%) are inflated 2–2.5pp by unrealized inventory gains
Normalized PAT margin (~5%) is below prior guidance anchor (4% core); operating leverage negative in near-term
FY27 guidance downgraded (volume, value); management hedged with caveats ('sticking to', 'estimated target', 'could revise')
Negative operating cash flow by design (inventory-ready model) requires continuous external capital; ₹100 Cr rights issue needed
Other expenses surged 132% YoY (vs 144% revenue); cost structure inflating faster than volume absorption
Marol (June start) and Jaipur (Nov-Dec expected) both early-stage; execution risk on capex, timeline, ramp
International business only 4% of Q1 revenue; Dubai RBI approval still pending; upside unproven
Risks, ranked by severity to a holder
Margin quality deterioration masked by accounting gains
HighNormalized EBITDA (7.5–8%) and PAT (4–5%) are below guidance (4% core PAT). If inventory gains don't repeat, Q2+ will show margin compression vs. Q1 headline. Investors pricing Q1 at face value may be surprised by normalized run-rate.
Working capital intensity + negative OCF model
HighRevenue +145%, PAT +47%, but cash generation negative by design. ₹100 Cr rights issue required; debt-to-equity rising to <1.0x. If growth slows but inventory must be maintained, cash burn accelerates. Capital dependent, not self-funding.
New facility execution risk (Marol ramp, Jaipur timeline)
HighMarol only 1 month operational in Q1; Jaipur expected Nov-Dec but factory work ongoing (schedule tight). If either slips or ramps below expectations, margin improvement from capacity leverage delays or stalls. Margin recovery depends on this.
Guidance downgraded but not followed by re-rating
HighVolume guidance cut (35–40% → 30–40%), value guidance cut (60–70% → 50–60%). Management signal caution. If market hasn't priced in lower growth trajectory, re-rating downward when it sinks in could pressure stock.
Other expenses inflating faster than volume
MediumOther expenses +132% YoY vs. revenue +144%. Cost structure inflating faster than absorption. If this trend continues, margin improvement from scale is delayed. Management cited 'growth support' but provided no breakdown.
Gold price volatility in a narrow band
MediumCurrent range ₹142–150. If gold rallies sharply, realization could compress (less premium on studded mix). If gold falls, inventory values mark down. Macro tail risk.
International expansion unproven (Dubai RBI approval pending)
MediumOnly 4% of Q1 revenue. RBI approval still pending. Upside claimed ('huge potential') but numbers vague, execution unproven. If geopolitical instability persists, expansion stalls.
How the street is positioned
Price action: The stock rallied +7.26% on day 1 post-results and held the bounce into day 3 (+9.94%), a sign the market initially bought the headline growth story. Stock now at ₹254.06, above all key moving averages (SMA20 ₹228.97, SMA50 ₹222.6, SMA200 ₹209.89), trading 5.55% below its all-time high (₹269) and 63.99% above the 52-week low (₹154.92). Volume trend is increasing. On technical grounds, bullish setup, though RSI at 69.9 signals stretched momentum in the near-term.
Institutional flows: FII and DII are actually trimming, not adding. FII ownership fell 26 bps QoQ to 1.92% (from 2.18%), DII fell 55 bps to 1.58% (from 2.13%). Promoter holding remains stable at 74.89%. The post-result pop is being met with institutional selling — a divergence worth noting. Bulk/block deals around Aug 14 (rights issue announcement date) show trading in the ₹242–244 range, slightly below current price; no sign of insider accumulation or panic selling.
Valuation context: The stock recovered most of its YTD losses and is now at premium to its SMA200 (+20.96%). However, the drawdown from ATH (₹269) is modest (−5.55%), suggesting the market has not yet repriced for margin deterioration or guidance cuts. If normalized earnings (₹36–38 Cr PAT vs. ₹50.5 Cr reported) sink in, there is room for re-rating downward.
The debate
The honest read: Shanti Gold is riding genuine industry tailwinds (organized retail shift, volume growth in a large under-penetrated market). The 61% volume growth is authentic and validates the bull thesis. But Q1 profit quality is compromised by accounting gains that will not repeat, and management's guidance downgrade is a warning signal on near-term execution. Normalized margins compress below guidance, working capital is a capital sink, and new facility ramp is unproven. The story is intact for the long-term (capacity, scale, mix improvement), but the near-term is cloudier than the market is pricing. The stock's +9.94% pop on day 3 suggests the market is pricing 'best case' (full guidance delivery, facilities on time, margin recovery). The odds of that are real but not certain. Prudent holders should wait for Q2 organic results and early Jaipur delivery evidence before adding.
What to watch next
1 · Q2 FY27 organic margin (Sep-Oct)
Does normalized EBITDA/PAT margin (ex-inventory gains) hold at 7.5–8% / 4%, or compress further? This is the crux. If Q2 margins are soft absent the inventory gain, re-rating downward likely.
2 · Marol ramp contribution (Q2-Q3)
Facility commissioned June, only 1 month in Q1 results. Q2/Q3 should show meaningful contribution from new 4,000 kg line. Management promised 'better results coming'; evidence critical to validate margin recovery thesis.
3 · Jaipur facility progress (Nov-Dec 2026)
Expected operational by mid-Nov to Dec. ₹47 Cr capex, 1,200 kg added capacity, first phase of 3-acre campus. Timeline is tight; slippage would be a red flag. On-time commissioning critical for FY27 upside.
4 · Rights issue deployment (H2 FY27)
₹100 Cr (46.43L shares) opened Aug 14. Monitoring: (a) subscription rate, (b) use of proceeds (inventory, capex, working capital), (c) impact on D/E and RoE. Capital-efficiency under scrutiny.
5 · Dubai RBI approval (Q3 or later)
International business only 4% of revenue; RBI approval pending. Even modest approval would be validation of long-term growth case. Unblocks geopolitical upside ('when wars settle').
What to track from here
The number to monitor is normalized PAT margin (stripping inventory gains). If it holds at 4–5% going forward, the normalized earnings power is ~₹28–36 Cr per ₹716 Cr run-rate revenue. That's the economic reality. The reported 7.05% PAT margin in Q1 is a one-time luxury; don't plan on it repeating. A stock that repays capital on ₹28–36 Cr normalized earnings (vs. ₹50.5 Cr reported) at ₹254 is a different valuation story than what the market is implying today.
Shanti Gold's Q1 is a quality vs. quantity story. Volume growth (+61%) is real, revenue (+145%) is genuine, and the organized retail tailwind is structural. But profit growth (+47%) lags because operating leverage is negative in this ramp phase. Normalized margins compress below guidance, and guidance itself was downgraded. This is not yet an earnings miss — it's a guidance recalibration and a signal that management is cautious on near-term delivery.
The long-term thesis (capacity expansion, product mix, scale) remains sound. But near-term execution is in question: new facilities are early-stage, working capital is a capital sink, and the profit conversion math is softer than headline growth implies. For investors who own this stock, the Q1 rebound (+9.94% pop) is a gift — use it to clean up positions or take profits. For buyers at ₹254, the risk/reward is balanced; the upsides are real but so are the execution risks. The margin recovery story (7.5–8% EBITDA, 4% PAT) needs to prove itself in Q2 onwards. Until then, a neutral stance is prudent.
Verdict: Hold. Rating reflects strong volume tailwinds offset by margin quality concerns and execution uncertainty. The bounce has priced in best-case guidance delivery. Wait for Q2 organic margin and Jaipur early evidence.